Further metabolite-based analysis may help identify the mechanisms underlying pulmonary dysfunction in COVID-19 survivors and provide potential therapeutic targets in the future.
Chronic obstructive pulmonary disease (COPD) is associated with lower use of beta-blockers and worse health status and is an independent predictor of cardiovascular and noncardiovascular hospitalizations.
In patients with COPD, subclinical left ventricular systolic dysfunction is likely to be detected when measured by tissue Doppler imaging, even in patients without pulmonary hypertension.
Thoracic organ transplantation remains a viable treatment option in patients with Eisenmenger Syndrome, although these patients are considered higher risk than other potential transplant recipients.
Bayesian machine learning algorithms can improve discrimination of risk stratification in pulmonary arterial hypertension.
In patients with pulmonary arterial hypertension, renal function is important for determining mortality risk and improves stratification of risk.
Children with congenital heart disease and comorbid obstructive sleep apnea are at increased risk for impaired neurocognition compared with children with congenital heart disease who do not have comorbid OSA.
Combination therapy is appropriate for patients with typical pulmonary arterial hypertension who are categorized as low and intermediate risk at baseline.
Among patients with asthma and chronic obstructive pulmonary disease overlap, long-acting beta2-agonist therapy is associated with a decreased risk for myocardial infarction.
Cardiac magnetic resonance imaging is useful for risk stratification in patients with pulmonary arterial hypertension.
